Analysis of costs of patients with diabetes 2 in the Czech statutory health insurance system
| Author: | Bc. Magdalena Škodová |
|---|---|
| Year: | 2018 - summer |
| Leaders: | MUDr. Pavel Hroboň |
| Consultants: | |
| Work type: | Bachelors |
| Language: | Czech |
| Pages: | 64 |
| Awards and prizes: | |
| Link: | https://is.cuni.cz/webapps/zzp/detail/191684/ |
| Abstract: | This thesis examines costs of type 2 diabetes for health insurance companies and occurrence of this disease in Czech Republic. Diabetes mellitus is a serious chronical disease, the prevalence and treatment costs of which have raised over last few years all over the world, while capturing a large part of expenditures of health systems. The aim of this study is to introduce particular methods that may be used to identify individuals with diabetes from available datasets and subsenquently analyze the expenses from the view of Czech health insurance companies. Studies published to date does not seem to be relevant anymore or they examine a small sample of patients. The thesis should provide accurate and actual information since it uses datasets from 2015 provided by health insurance companies and data containing individual costs of policyholders. In order to identify diabetics two approaches are used – diagnosis and various quantities of drug consumption of typical pharmaceuticals. The study implies that the costs of the treatment of diabetes fall between 19 and 44 billion CZK annualy depending on applied method. The analysis also suggests that the average costs are rising along with higher age of diabetic and these costs are more than 2-fold higher when compared to common population. In reaction to discovered discrepancies in current system, author provides some possibilities how to improve it. Furthermore, the results of this research might help to specify the amount of drug consumption, which is currently used as one of the criteria for setting the amount of funds, which is redistributed to health insurance companies |
